Barclays PLC Acquires 231,578 Shares of Hologic, Inc. (NASDAQ:HOLX)

Barclays PLC raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 47.6% during the third quarter, HoldingsChannel reports. The fund owned 718,231 shares of the medical equipment provider’s stock after purchasing an additional 231,578 shares during the quarter. Barclays PLC’s holdings in Hologic were worth $58,507,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in HOLX. Cetera Investment Advisers grew its position in shares of Hologic by 188.9% during the 1st quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after purchasing an additional 13,380 shares in the last quarter. Andra AP fonden grew its position in Hologic by 224.5% during the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock worth $7,083,000 after buying an additional 66,000 shares in the last quarter. GAMMA Investing LLC increased its stake in Hologic by 17.9% in the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock worth $312,000 after acquiring an additional 582 shares during the last quarter. Quest Partners LLC raised its holdings in shares of Hologic by 56.1% in the 2nd quarter. Quest Partners LLC now owns 41,492 shares of the medical equipment provider’s stock valued at $3,081,000 after acquiring an additional 14,914 shares in the last quarter. Finally, Versor Investments LP bought a new stake in shares of Hologic during the 3rd quarter valued at about $1,677,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HOLX. Royal Bank of Canada upped their price objective on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Leerink Partners decreased their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. UBS Group lifted their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and reduced their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Five equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.50.

Hologic Trading Down 0.6 %

NASDAQ HOLX opened at $75.09 on Friday. The firm has a market capitalization of $17.04 billion, a PE ratio of 22.55, a P/E/G ratio of 2.37 and a beta of 0.96. The stock’s 50 day moving average is $79.45 and its 200 day moving average is $78.56. Hologic, Inc. has a twelve month low of $69.36 and a twelve month high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period in the prior year, the firm earned $0.89 EPS. The company’s revenue was up 4.5% compared to the same quarter last year. Research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.75% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.